Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation

In the final episode, 'Access, Coverage, and Final Reflections on Managing Alzheimer's Disease Agitation,' the panelists explored the following critical questions: How has insurance coverage been with the Food and Drug Administration (FDA)-approved therapies for Alzheimer's disease agitation?What are best practices in working with insurance providers to get coverage for patients? Anton Porsteinsson described the payer landscape for both approved agents as initially challenging, with step edits and prior authorization requirements commonly encountered as insurers accustomed to gating branded medications in conditions with many available generic alternatives applied similar restrictions to these new agents. He noted that over time, persistence and clinical advocacy have helped, including directly communicating to payers that requiring patients to first try off-label, unapproved agents with inferior evidence profiles and known safety risks in a population where approved options now exist raises significant ethical and medical-legal concerns. Alireza Atri emphasized the importance of manufacturer patient assistance programs as a meaningful resource for patients on fixed incomes who face cost barriers given that both agents are branded without generic availability, and offered a compelling closing perspective that early identification, accurate diagnosis, and appropriate management of Alzheimer's disease agitation represents an approach that is medically, ethically, morally, and economically sound for all stakeholders. Dr. Porsteinsson closed with a call to action for providers, caregivers, and patients alike, reinforcing that agitation is common, distressing, and highly impactful on quality of life, but that with the right awareness, structured evaluation, and access to effective treatments, clinicians can make a meaningful and lasting difference in the lives of patients and their loved ones. Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward. Thank you for watching this Peer Exchange series on Alzheimer's disease agitation. Please subscribe to our newsletter for information on upcoming video series.